2013-10-01 11:42 PM
INGELHEIM, Germany--(BUSINESS WIRE)--Oct 1, 2013--For media outside of the U.S.A., UK and Canada only
Ten abstracts featuring Boehringer Ingelheim's investigational hepatitis C virus (HCV) protease inhibitor, faldaprevir * and polymerase inhibitor, deleobuvir * will be presented at the 64 th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2013, 1-5 November, Washington. 1
Faldaprevir * is a second generation protease inhibitor and is the foundation of Boehringer Ingelheim's interferon-based and interferon-free treatment regimens.
The accepted abstracts include final results from the Phase III STARTVerso?1 and 2 studies, investigating the treatment regimen of faldaprevir * in combination with pegylated interferon and ribavirin. Also data in difficult-to-treat populations such as treatment-experienced (STARTVerso?3 ?V final data) and HCV/HIV co-infected (STARTVerso?4 ?V end of treatment data) patients will be presented at the meeting, adding to the comprehensive portfolio of data for faldaprevir in HCV. The STARTVerso? trial results form the basis for regulatory submissions of faldaprevir.
Boehringer Ingelheim's comprehensive hepatitis C clinical trial programme includes a broad range of the type of patients that clinicians see every day in clinical practice. The company's goal is to develop effective and well tolerated treatments recognising the unmet need for more patient centric approaches in hepatitis C.
Boehringer Ingelheim's abstracts can be accessed on the AASLD website today at www.aasld.org. Details of the poster presentations can be found below.
# # #
NOTES TO EDITORS
The Boehringer Ingelheim NewsHome: An innovative resource for journalists
The Boehringer Ingelheim hepatitis C www.NewsHome.com is the one-stop-shop for clear, concise and easy to understand information about hepatitis C for media.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
1 American Association for the Study of Liver diseases (AASLD). The Liver MeetingR Abstract Central. http://aasld2013.abstractcentral.com/viewer
[Last accessed 1 October, 2013]
* Faldaprevir and deleobuvir (BI 207127) are investigational compounds and not yet approved. Their safety and efficacy have not yet been fully established.
CONTACT: Boehringer Ingelheim
Media + PR
Tel: +49 (6132) 77-90815
Fax: +49 (6132) 77-6601
KEYWORD: EUROPE GERMANY
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Boehringer Ingelheim
Copyright Business Wire 2013
PUB: 10/01/2013 11:20 AM/DISC: 10/01/2013 11:20 AM